Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795274 | 0.95 | MDM2 (0.43) | MDM2MAPK1SMN1; SMN2LMNAHTT | |
| SCHEMBL21925720 | 0.81 | SMN1; SMN2 (0.38) | MAPK1SMN1; SMN2 | |
| SCHEMBL9263204 | 0.80 | SMN1; SMN2 (0.43) | MAPK1SMN1; SMN2LMNAHTTHSD17B10 | |
| SCHEMBL21925718 | 0.78 | SMN1; SMN2 (0.53) | MDM2MAPK1SMN1; SMN2LMNAHTT | |
| SCHEMBL11691096 | 0.77 | SMN1; SMN2 (0.43) | MAPK1SMN1; SMN2LMNAHTTHSD17B10 | |
| SCHEMBL29895266 | 0.77 | SMN1; SMN2 (0.43) | MAPK1SMN1; SMN2LMNAHTTHSD17B10 | |
| SCHEMBL28449071 | 0.73 | ALDH1A1 (0.46) | MAPK1SMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL28921782 | 0.73 | SLC6A2 (0.39) | MDM2MAPK1SMN1; SMN2LMNAHTT | |
| SCHEMBL21925724 | 0.71 | TP53 (0.49) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL23795275 | 0.71 | TP53 (0.49) | SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | DOTTIKON ES HOLDING AG (CH) | 2024-10-22 | — | — | US | disclosed |
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2022-01-06 | — | — | US | disclosed |
| EP-3877357-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | NR0B2, KCNJ2, TRRAP | MDM2 1832/4885MAPK1 3085/4885SMN1; SMN2 3918/4885 |
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | NR0B2, KCNJ2, TRRAP | MDM2 1832/4885MAPK1 3085/4885SMN1; SMN2 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.